metralindole

Metralindole is a reversible inhibitor of monoamine oxidase A (RIMA).

Metralindole is a reversible monoamine oxidase A (RIMA) inhibitor, it was investigated as a potential antidepressant.

Pirlindole, a reversible inhibitor of monoamine oxidase A (RIMA), has been developed and used primarily as an antidepressant compound in Russia. Structurally and pharmacologically, it is similar to metralindole. Pirlindole has received approval for the treatment of depression in several European and non-European countries. Its oral absolute bioavailability ranges from 20% to 30%, mainly due to significant first-pass metabolism. In rats, the oral Tmax varies between 2.5 and 6 hours, while in dogs, it ranges from 0.8 to 2 hours.

Pirlindole, a reversible inhibitor of monoamine oxidase A (RIMA), was developed and is used as an antidepressant in Russia. It is structurally and pharmacologically related to metralindole. Pirlindole has been approved for the treatment of depression in several European and non-European countries. Due to extensive first-pass effects, its absolute bioavailability ranges from 20% to 30%. When administered orally, the Tmax in rats varies from 2.5 to 6 hours, while in dogs it ranges from 0.8 to 2 hours.

Pirlindole is a reversible inhibitor of monoamine oxidase A (RIMA). It is structurally and pharmacologically related to metralindole.